Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Dino's Bar & Grill -- Ignore unavailable to you. Want to Upgrade?

To: Goose94 who wrote (94144)	9/17/2020 10:34:05 AM
From: Goose94	Read Replies (1) \| Respond to of 203028

Immunoprecise Antibodies (IPA-V) new 52 week high, $2.26

To: Goose94 who wrote (94144)	9/29/2020 8:56:08 AM
From: Goose94	Read Replies (2) \| Respond to of 203028

Immunoprecise Antibodies (IPA-V) Industrial Alliance Securities analyst Chelsea Stellick says Immunoprecise Antibodies has reached a "pivotal moment" with the start of pre-clinical trials for its vaccine trails against SARS-CoV-2. Victoria-based company announced it has commenced trials with the Netherland's LiteVax BXC based on large sets of data obtained during the analysis of its SARS-CoV-2 therapeutic programs. With LiteVax's adjuvant technology, they are aiming for a single-low-dose administration. Results of the collaborative, pre-clinical study are expected by November. Ms. Stellick says in a note: "We believe this is a pivotal move for the company as it develops a more pharma-based business model approach, while leveraging the internal clinical experience of the CRO business unit. The initiation of pre-clinical trials indicates the crystallization of the Talem business segment and the acceleration of IPA." Keeping a "buy" rating for Immunoprecise shares, Ms. Stellick increased her share target to $3, matching the current consensus, from $2.50. Message 32950472